TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9528844

Group type: EXPERIMENTAL
Intervention: Ifosfamide (3 g m(‐2) x (2 or 3) days as a 1‐h bolus)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ifosfamide (same total dose as continuous infusion)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg 8 hourly for 3 days starting 8 h before IFOS (for two cycles)
Number of subjects: 11
Study: 7598087

Group type: EXPERIMENTAL
Intervention: Acupoint LI-4 (Hoku) stimulation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-acupuncture point stimulation
Number of subjects: 21
Study: 2650643

Group type: EXPERIMENTAL
Intervention: Early excision
Number of subjects: 85

Group type: COMPARATOR
Intervention: Topical antimicrobial therapy and skin grafting after spontaneous eschar separation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Early excision and topical antimicrobial therapy
Number of subjects: 85
Study: 1159265

Group type: EXPERIMENTAL
Intervention: Diazepam (12 mg daily for two weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30987663

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) supplementation (0.2 g/kg body mass)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (HCO3--free beverage)
Number of subjects: 20
Study: 26711938

Group type: EXPERIMENTAL
Intervention: Tooth sectioning performed (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No tooth sectioning performed (Group A)
Number of subjects: 100
Study: 24861133

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg single oral dose) plus Cyclosporine (600 mg single oral dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ticagrelor alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 26
Study: 22648712

Group type: COMPARATOR
Intervention: [¹³C]Palmitate and octanoate administered via gastrointestinal endoscopy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Portal-systemic shunt treatment in the PH(+)LC group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intestinal specimens examination in PH(+)LC group
Number of subjects: 67

Group type: COMPARATOR
Intervention: High serum concentrations of glucagon-like peptide-2 in PH(+)LC group
Number of subjects: 67
Study: 20723619

Group type: EXPERIMENTAL
Intervention: ActiGraph monitor
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239
Study: 18221433

Group type: EXPERIMENTAL
Intervention: Oral controlled-release alpha-lipoic acid (CRLA) for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16318978

Group type: EXPERIMENTAL
Intervention: 20 mg dydrogesterone per day during the first trimester of pregnancy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12629248

Group type: EXPERIMENTAL
Intervention: tau H1/H1 genotype
Number of subjects: 25

Group type: COMPARATOR
Intervention: No mutations detected
Number of subjects: 25
Study: 12569789

Group type: EXPERIMENTAL
Intervention: Re-Du-Qing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1992214

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lovastatin with low-fat diet
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lovastatin with high-fat diet
Number of subjects: 35

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 35
Study: 6882816

Group type: EXPERIMENTAL
Intervention: Medium sensitivity feedback
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low sensitivity feedback
Number of subjects: 34

Group type: COMPARATOR
Intervention: High sensitivity feedback
Number of subjects: 34
Study: 31417102

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100 μg/25 μg or 200 μg/25 μg
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 29656442

Group type: EXPERIMENTAL
Intervention: Lenvatinib (24 mg/d on a 28-day cycle)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 26756115

Group type: EXPERIMENTAL
Intervention: Insulin during euglycemic hyperinsulinemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: METsYN subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline and post-insulin clamp
Number of subjects: 0
Study: 24216218

Group type: EXPERIMENTAL
Intervention: Weaning to formula containing hydrolyzed cow's milk protein
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Weaning to formula containing intact cow's milk protein
Number of subjects: 5000
Study: 22167541

Group type: EXPERIMENTAL
Intervention: Travoprost BAK-free
Number of subjects: 371

Group type: COMPARATOR
Intervention: Travoprost BAK
Number of subjects: 371
Study: 19907417

Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17613258

Group type: EXPERIMENTAL
Intervention: MT-BMSCs (bone marrow stromal cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M-PCs (periosteal cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MT-BMSCs and M-PCs
Number of subjects: 0
Study: 15828852

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg famotidine (single dose, intravenous or oral)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg/dose intravenously or 0.5 mg/kg/dose orally (multiple doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/dose intravenously or 1 mg/kg/dose orally (subsequent doses)
Number of subjects: 36
Study: 12135452

Group type: EXPERIMENTAL
Intervention: Out-patient multicomponent training program including strength training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 68
Study: 10321172

Group type: EXPERIMENTAL
Intervention: Epi-Guide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Guidor
Number of subjects: 40
Study: 8625185

Group type: EXPERIMENTAL
Intervention: Pelvic intraarterial chemotherapy (IAC) with mitomycin-C (10 mg/m2), vincristine (1 mg/m2), and cisplatin (50 mg/m2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pelvic intraarterial chemotherapy (IAC) with mitomycin-C (10 mg/m2), vincristine (1 mg/m2), and cisplatin (75 mg/m2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pelvic intraarterial chemotherapy (IAC) with cisplatin (75 mg/m2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pelvic intraarterial chemotherapy (IAC)
Number of subjects: 21
Study: 1852090

Group type: COMPARATOR
Intervention: Dobutamine (15 micrograms/kg/min for 24 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Milrinone (24-hour infusion)
Number of subjects: 20
Study: 6154200

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 or 0.2 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30675700

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde biliary drainage (ERBD)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic cholangiography and drainage (PTCD)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: No preoperative biliary drainage (non-PBD)
Number of subjects: 899

Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 899
Study: 28389510

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone for 24 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: LNCaP cells expressing SLCO2B1
Number of subjects: 58
Study: 26923644

Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Passive mobilization (Control)
Number of subjects: 31
Study: 24518789

Group type: EXPERIMENTAL
Intervention: Beef
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fish
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chicken
Number of subjects: 15
Study: 22945718

Group type: EXPERIMENTAL
Intervention: Laser + Prompt L‐Pop
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Air abrasion + phosphoric acid etching
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser + etching
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Air abrasion + Prompt L‐Pop
Number of subjects: 60
Study: 19576277

Group type: EXPERIMENTAL
Intervention: Oral sodium nitrite (0.12 mmol NaNO(2)/mmol Hb)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral sodium nitrite (0.06 mmol NaNO(2)/mmol Hb)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite (0.12 mmol NaNO(2)/mmol Hb)
Number of subjects: 9
Study: 17689624

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.625 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.625 mg and medroxyprogesterone acetate (MPA), 2.5 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.45 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.45 mg and medroxyprogesterone acetate (MPA), 2.5 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.45 mg and medroxyprogesterone acetate (MPA), 1.5 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.3 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.3 mg and medroxyprogesterone acetate (MPA), 1.5 mg
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 15453549

Group type: EXPERIMENTAL
Intervention: Ropinirole (0.25-4.0 mg per day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 11606148

Group type: EXPERIMENTAL
Intervention: Sustained-release sodium fluoride, calcium citrate, and cholecalciferol (SR-NaF group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Calcium and cholecalciferol (control group)
Number of subjects: 85
Study: 9613265

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol at 5 micrograms.ml‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol at 6 micrograms.ml‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol at 7 micrograms.ml‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol at 8 micrograms.ml‐1
Number of subjects: 60
Study: 7983121

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty after patellectomy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Total knee arthroplasty with intact patella (Control)
Number of subjects: 19
Study: 2189430

Group type: EXPERIMENTAL
Intervention: Hydergine (ergoloid mesylates)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 422738

Group type: EXPERIMENTAL
Intervention: Loading regimen of 2600 mg ASA divided into two equal doses 4 hours apart
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group received 650 mg ASA every 4 hours for 48 hours
Number of subjects: 6
Study: 31961048

Group type: EXPERIMENTAL
Intervention: Co-enhancer cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Branded cream control
Number of subjects: 0
Study: 30804992

Group type: EXPERIMENTAL
Intervention: CareToy intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 44
Study: 28082519

Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 25580697

Group type: EXPERIMENTAL
Intervention: Individual definitions of pain flare
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Quality of pain flare (often sharp)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Agreement with supplied definition of pain flare
Number of subjects: 45
Study: 22781385

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg intravenously every 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pamidronate 90 mg intravenously every 3 to 4 weeks (control)
Number of subjects: 38
Study: 20658541

Group type: EXPERIMENTAL
Intervention: Colposuspension
Number of subjects: 157

Group type: COMPARATOR
Intervention: Anterior repair plus TVT
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 157
Study: 20008710

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 3838

Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 3838

Group type: COMPARATOR
Intervention: Topical antibiotics (given on the day of injection)
Number of subjects: 3838

Group type: COMPARATOR
Intervention: Topical antibiotics (given after injection)
Number of subjects: 3838

Group type: COMPARATOR
Intervention: Topical antibiotics (both before and after injection)
Number of subjects: 3838

Group type: COMPARATOR
Intervention: No topical antibiotics
Number of subjects: 3838
Study: 18020936

Group type: EXPERIMENTAL
Intervention: Fast-Lane (FL)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Fast-Lane with boosters (FL + B)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Diet-and-exercise attention-control (D&E)
Number of subjects: 451
Study: 15499601

Group type: EXPERIMENTAL
Intervention: SIR-Spheres plus fluorouracil/leucovorin chemotherapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Fluorouracil/leucovorin chemotherapy alone
Number of subjects: 21
Study: 11573600

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 150 IU ml(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 15 IU ml(‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2% lidocaine and 1% ropivacaine without hyaluronidase
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2% lidocaine and 1% ropivacaine with hyaluronidase 15 IU ml(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2% lidocaine and 1% ropivacaine with hyaluronidase 150 IU ml(‐1)
Number of subjects: 90
Study: 9745061

Group type: EXPERIMENTAL
Intervention: Intermittent sequential compression device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pseudopneumoperitoneum (PPP) model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real pneumoperitoneum (PP) at 14 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased intraabdominal pressure
Number of subjects: 0
Study: 7908076

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 2316
Study: 2575376

Group type: EXPERIMENTAL
Intervention: Instructions to focus upon feared somatic sensations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Instructions to engage in distracting tasks
Number of subjects: 30
Study: 1106218

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 0
Study: 31542129

Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes (0.4 mg nicotine/g tobacco)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 240

Group type: COMPARATOR
Intervention: Very low nicotine content cigarettes (0.4 mg nicotine/g tobacco) with transdermal nicotine patch
Number of subjects: 240
Study: 27935076

Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 24588277

Group type: EXPERIMENTAL
Intervention: Topical ointment (Aquaphor Original Emollient)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Routine skin care
Number of subjects: 197
Study: 23164480

Group type: EXPERIMENTAL
Intervention: prednisolone 7.5mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: prednisolone 30mg once daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study: 21107748

Group type: EXPERIMENTAL
Intervention: 3.0 g/l propofol (n = 64)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Physiological saline (placebo) (n = 39)
Number of subjects: 103
Study: 19273450

Group type: EXPERIMENTAL
Intervention: High MBL2 expression genotypes (O/O, A/O, A/A)
Number of subjects: 158
Study: 16893569

Group type: EXPERIMENTAL
Intervention: Minimally depressed subjects
Number of subjects: 206

Group type: COMPARATOR
Intervention: Nondepressed subjects
Number of subjects: 206
Study: 15356807

Group type: EXPERIMENTAL
Intervention: Restricted physiologic diet
Number of subjects: 105

Group type: COMPARATOR
Intervention: Unrestricted diet
Number of subjects: 105
Study: 11397886

Group type: EXPERIMENTAL
Intervention: Children treated for ALL
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy British children (comparison group)
Number of subjects: 68
Study: 9438318

Group type: EXPERIMENTAL
Intervention: OAC (20 mg omeprazole, 750 mg amoxicillin, and 250 mg clarithromycin, twice daily for 10 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: BTC (240 mg bismuth subcitrate, 750 mg oxytetracycline, and 250 mg clarithromycin, twice daily for 10 days)
Number of subjects: 61
Study: 8483424

Group type: EXPERIMENTAL
Intervention: 3 implants, each containing 12 mg oestradiol valerate (E2V)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 implants, each containing 27 mg oestradiol benzoate (E2B)
Number of subjects: 10
Study: 3717960

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of THP, 5-Fluorouracil and cyclophosphamide (Group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Adriamycin, 5-Fluorouracil and cyclophosphamide (Group B)
Number of subjects: 64
Study: 29415523

Group type: EXPERIMENTAL
Intervention: Cessation benefit topics and imagery types (DCE 1)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Messages with tips to improve cessation success and imagery types (DCE 2)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Reproductive health benefits of cessation topics and imagery types (DCE 3)
Number of subjects: 1000
Study: 27768984

Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (BF)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Active relaxation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waiting control condition
Number of subjects: 84
Study: 25219128

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Warm-needling
Number of subjects: 133

Group type: COMPARATOR
Intervention: Non-acupoint
Number of subjects: 133
Study: 21809090

Group type: EXPERIMENTAL
Intervention: WBV + RES
Number of subjects: 29

Group type: COMPARATOR
Intervention: PL + RES
Number of subjects: 29
Study: 21250568

Group type: EXPERIMENTAL
Intervention: Toothpaste with 5% d‐limonene combined with Perlite whitening formulation
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Toothpaste with 5% d‐limonene alone (negative formulation)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Positive control with perlite whitening formulation
Number of subjects: 408

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 408
Study: 17943257

Group type: EXPERIMENTAL
Intervention: Combination therapy of TNF inhibitors (etanercept, infliximab, adalimumab) plus methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF-blocking agents (etanercept, adalimumab, infliximab)
Number of subjects: 0
Study: 15743421

Group type: EXPERIMENTAL
Intervention: Thermafil (TF)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Lateral Condensation (LC)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both TF and LC
Number of subjects: 79
Study: 12787302

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 11764116

Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser energy at 240 mJ
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser energy at 200 mJ
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser energy at 300 mJ with 100 mJ finish
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (conventional diamond bur)
Number of subjects: 60
Study: 8723581

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (100 IU/kg s.c. on days -30, -23, -16, and -9 prior to surgery) with oral iron supplementation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (200 IU/kg s.c. on days -30, -23, -16, and -9 prior to surgery) with oral iron supplementation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 1517652

Group type: EXPERIMENTAL
Intervention: Oxygen 5 L/min delivered by mask
Number of subjects: 1

Group type: COMPARATOR
Intervention: Air 5 L/min delivered by mask
Number of subjects: 1
Study: 6367246

Group type: EXPERIMENTAL
Intervention: 0.15 mg beta-methyl digoxin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.20 mg beta-methyl digoxin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31508878

Group type: EXPERIMENTAL
Intervention: Early dutasteride initiation
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Late initiation
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Early initiation
Number of subjects: 1206
Study: 30814213

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 177

Group type: COMPARATOR
Intervention: Historical cohort (physician discretion)
Number of subjects: 177
Study: 26660956

Group type: EXPERIMENTAL
Intervention: Laparoscopic prophylactic inguinal lymphadenectomy with saphenous vein sparing
Number of subjects: 23

Group type: COMPARATOR
Intervention: Laparoscopic prophylactic inguinal lymphadenectomy with saphenous vein ligated
Number of subjects: 23
Study: 25223378

Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22906144

Group type: EXPERIMENTAL
Intervention: Active acupuncture treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 33